Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
62.1M
-
Shares change
-
+1.44M
-
Total reported value, excl. options
-
$3.13B
-
Value change
-
+$81M
-
Put/Call ratio
-
0.67
-
Number of buys
-
68
-
Number of sells
-
-42
-
Price
-
$50.42
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q3 2024
141 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q3 2024.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.1M shares
of 63.5M outstanding shares and own 97.82% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (8.49M shares), FMR LLC (4.95M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.98M shares), Avoro Capital Advisors LLC (2.77M shares), CITADEL ADVISORS LLC (2.32M shares), Holocene Advisors, LP (1.59M shares), GOLDMAN SACHS GROUP INC (1.5M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (1.17M shares), and MARSHALL WACE, LLP (1.15M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.